Study of the PAS-Port® Proximal Anastomosis System in Coronary Bypass Surgery
NCT ID: NCT00355563
Last Updated: 2009-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
220 participants
INTERVENTIONAL
2006-06-30
2008-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery
NCT01334866
Safety and Effectiveness of the Medtronic Resting Heart Bypass System in Heart Surgery Patients
NCT00303641
Biologically Modified Saphenous Vein Transplants for Improved CABG Outcomes
NCT01313533
Transepicardial With Transseptal Autologous CD 133+ Bone Marrow Cell Implantation in Patient Following CABG Surgery
NCT02870933
A Single Center Clinical Evaluation of Same Sitting Hybrid Revascularization: Robotic Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention for the Treatment of Coronary Artery Disease
NCT00928356
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PAS-Port Automated Proximal Anastomosis System
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Assessment that the patient is willing and able to have follow-up visits and examinations
* Age greater than or equal to 50 years and less than 85 years
* Ejection fraction of \>30%
* Can tolerate radiographic contrast media
* Requires non-emergent coronary artery bypass with at least two vein bypass grafts intended
* Coronary artery targets intended for bypass index grafts must have \>70% native stenosis
* Life expectancy \>1 year
* Patient is hemodynamically stable
* Open chest reassessment of the revascularization strategy confirms that two vein bypass grafts are still intended
* Target vessel wall properties that are suitable for performing both a hand-sewn and a PAS-Port anastomosis
* Target vessel is greater than 1.8 mm in diameter at sites where anastomoses are planned
* Target vessel at sites where anastomoses will be placed are free from severe calcifications or severe atheromas
* The length of the vein graft(s) is adequate for both of the planned index graft revascularization strategies
* Vein outside diameter and double wall thickness are between 4 and 6 mm(inclusive) and less than or equal to 1.4 mm, respectively, at the graft site intended for the PAS-Port proximal anastomosis
* The vein(s) is of suitable quality to be used as a bypass graft conduit
Exclusion Criteria
* Unable to meet study requirements (travel, general health)
* Pregnancy
* Previous cardiac surgery
* Requiring preoperative use of an intraaortic balloon pump
* Congestive heart failure / NYHA Class IV
* History of thromboembolic disease requiring ongoing anticoagulation therapy or the presence of a bleeding disorder
* Acute or chronic dialysis
* Creatinine of greater than 200 µmol/L (2.3 mg/dL) in the last 30 days
* Documented acute or suspected systemic infection
* Need for ongoing immunosuppressive therapy
* Recent (less than 2 weeks) history of cerebrovascular accident
* Aspirin allergy or other contraindications to aspirin use
INTRA-OPERATIVELY
50 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cardica, Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cardica, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Puskas, M.D.
Role: PRINCIPAL_INVESTIGATOR
Emory University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Michael's Medical Center
Newark, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IP2005-07
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.